Macrocyclics

MDS Nordion is collaborating with Macrocyclics Inc., a privately held, Dallas, Texas-based company that conducts research and development, good manufacturing practices (GMP), synthesis, and makes accessible to the research community a variety of high purity ligands for nuclear medicine and magnetic resonance imaging applications.

The collaboration is focused on the development of innovative, bifunctional chelates for use in molecular imaging and targeted therapeutic pharmaceuticals. Bifunctional chelates are chemical compounds used to secure a radioisotope to a molecular targeting agent such as a monoclonal antibody, peptide, or other molecules specific for biologic receptors. The use of molecular targeting molecules is an established and increasingly promising technique that has the potential to significantly improve the ability to diagnose and treat disease, including cancer.

An outcome of this collaboration is the filing of patents covering innovative bifunctional chelates. We anticipate additional innovations arising from this collaboration.

New and Innovative Bifunctional Chelates

Developed through our collaborative research partnership with Macrocyclics, we’re proud to announce two new proprietary bifunctional chelates:

p-Bn-PCTA and p-Bn-Oxo-DO3A

Already showing promising properties in discovery research, these bifunctional chelates are applicable to numerous metal radioisotopes, including ⁶⁸Ga, ⁶⁴Cu, ¹¹¹In, ⁹⁰Y and ¹⁷⁷Lu. These novel proprietary bifunctional chelates, p-Bn-PCTA and p-Bn-Oxo-DO3A, are available* through Macrocyclics.

*These bifunctional chelates are owned by MDS Nordion and are the subject of patents pending.  Macrocyclics is permitted to sell this material to third-parties provided these materials are to be used solely for non-commercial research purposes. A separate license is required for any commercial use.  Commercial use includes, but is not limited to: use of this material to manufacture a product or provide a service, or the resale of this material. Information for a commercial license can be obtained from the Director, Science and Technology Partnerships, MDS Nordion, 447 March Rd., Ottawa, Canada, K2K 1X8; telephone: (613)-592-3400 Ext. 2292.

These materials are experimental in nature, are for laboratory use only and have not been approved for diagnostic or therapeutic use in humans and shall only be used in compliance with all laws and regulations applicable to their handling and safe use.